Brexit is understandably the talk of the town, yet there's still nothing to say of any gravity about it, nine months on from the UK's vote to leave the EU. So says Doris-Ann Williams MBE, chief executive of the British In Vitro Diagnostics Association (BIVDA), speaking to MedTech Insight early in the month that UK Prime Minister Theresa May finally invoked Article 50 of the Treaty of Lisbon, thereby beginning the divorce talks between the UK and the EU and its remaining 27 member states.
Amid Reforms, Brexit, UK IVD Firms Battle Funding And Adoption Issues
The EU In Vitro Diagnostics Regulation and Brexit loom large for UK IVD companies, but manufacturers serving the $1.6bn UK IVD market have many other competing concerns. It’s the most challenging period in more than 15 years, according to the British In Vitro Diagnostics Association Chief Executive Doris-Ann Williams.
More from United Kingdom
More from Europe
• By
Medtech has not yet been spared from the Trump administration’s trade tariffs, which, for UK exporters will be 10% – half the rate applied to EU27 exporters.
• By
Swiss medtech exporters seek urgent diplomatic action from the Swiss Federal Council in a bid to overturn the 2 April US decision to put tariffs on goods imports.
• By
A seemingly humorous social media post on April Fool’s Day struck a nerve with regulatory experts, reflecting real concerns about recent actions by the US Food and Drug Administration.